Abilify MyCite, the first digital pill. Where does all that silicone go?

Last Updated on

November 16, 2017 – The American Food & Drug Administration (FDA) just approved Ability MyCite,  a pill with a sensor that digitally tracks if patients have ingested their medication. This is a very first in its class at the new age of digital health.

Digital health. Th pill with the chip.

Originally  Aripiprazole (Abilify)  was approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults. The all new Aripiprazole (Abilify MyCite) (i.e., aripiprazole tablets with an sensor) is approved for the same indictions. It comes, however, with an ingestible sensor embedded in the pill that records that the medication was taken. Thus, the Abilify MyCite features a sensor the size of a grain of sand made of silicone, copper, and magnesium. An electrical signal is activated when the sensor comes into contact with stomach acid. A patch the patient wears on their left rib cage receives the signal several minutes after the pill is ingested. The patch then sends data like the time the pill was taken and the dosage to a smartphone app over Bluetooth. The patch also records activity levels, sleeping patterns, steps taken, activity, and heart rate, and must be replaced every seven days. The patient’s doctor and up to four other people chosen by the patient, including family members, can access the information. The patient can revoke access at any time. It is assumed that the sensor as such  passes through the body naturally.

Schizophrenia is a chronic, severe and disabling brain disorder. About 1 percent of Americans have this illness. Typically, symptoms are first seen in adults younger than 30 years of age. Symptoms of those with schizophrenia include hearing voices, believing other people are reading their minds or controlling their

Self portrait of a patient with Schizophrenia in the digital age.

thoughts, and being suspicious or withdrawn. Bipolar disorder, also known as manic-depressive illness, is another brain disorder that causes unusual shifts in mood, energy, activity levels and the ability to carry out day-to-day tasks. The symptoms of bipolar disorder include alternating periods of depression and high or irritable mood, increased activity and restlessness, racing thoughts, talking fast, impulsive behavior and a decreased need for sleep.

The drug label of Aripiprazole (Abilify MyCite), as does the drug label of the regular Aripiprazole (Abilify) which is approved since 2002, contains a Boxed Warning alerting health care professionals that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole (Abilify MyCite) is not approved to treat patients with dementia-related psychosis. The Boxed Warning also warns about an increased risk of suicidal thinking and behavior in children, adolescents and young adults taking antidepressants. The safety and effectiveness of Aripiprazole (Abilify MyCite) have not been established in pediatric patients. Patients should be monitored for worsening and emergence of suicidal thoughts and behaviors. Aripiprazole (Abilify MyCite) must be dispensed with a Patient Medication Guide that describes important information about the drug’s uses and risks. Other common adverse drug effects reported by patients taking Aripiprazole (Abilify) were nausea, vomiting, constipation, headache, dizziness, uncontrollable limb and body movements (akathisia), anxiety, insomnia, and restlessness. With Aripiprazole (Abilify MyCite, skin irritation at the site of the MyCite patch placement may occur in some patients.

Patients should be well aware of the fact that new technology per se does not alleviate the serious health problems that come along for some patients who take Aripiprazole (Abilify) or antidepressant drugs in general, or their compliance with treatment. However, according to FDA, being able to track ingestion of medications prescribed for mental illness may be useful for some patients, and FDA supports the development and use of new technology in prescription drugs and is committed to working with companies to understand how technology might benefit patients and prescribers. Thus, Aripiprazole (Abilify MyCite) comes after years of venture research between Japanese pharmaceutical company Otsuka and digital medicine service Proteus Digital Health, which makes the sensor. Aripiprazole (Abilify MyCite) is one way to address the prevalent problem of patients not taking their medication correctly, with the IMS Institute estimating that the improper and unnecessary use of medicine cost the US healthcare sector over $200 billion in 2012.

Some serious questions might arise around digital pills, however. One question would be on what a digital pill might mean for patient privacy. Some are worried that tracking such pills will be a step towards punishing patients who don’t comply for whatever reason with treatment. This could mean that digital pills have the potential to improve public health but also to foster more mistrust instead of trust between caregivers and patients. Not to forget the role of insurers who potentially will have access to all these patient data as well. A second question could be as to the health effects on patients who are continouly exposed to silicon and all the other materials who make up the sensor. Where does all that silicone go? And last but not least, how to prevent patients from simply deceiving the system by exposing the sensor to 1 N HCl outside of the body in order to trigger the communication?

_______________________

Tags: , , , , , , , , , ,
About the Author
thassodotcom Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Leave a Reply

Optional: Social Subscribe/Login




avatar
  Subscribe  
Notify of
Buy Tramadol
Guest

An outstanding share! I’ve just forwarded this onto a coworker
who had been doing a little research on this.
And he actually bought me lunch due to the fact that I
found it for him… lol. So let me reword this….

Thank YOU for the meal!! But yeah, thanks for spending time
to talk about this subject here on your website.

minecraft
Guest

Wonderful goods from you, man. I’ve understand your stuff previous to and you’re just extremely excellent.
I really like what you’ve acquired here, really like what you’re stating and the way in which you say it.

You make it enjoyable and you still take care of to keep it
sensible. I cant wait to read far more from you. This
is really a wonderful website.

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Descendants of early Europeans and Africans in US carry Native American genetic legacy September 19, 2019
    Many people in the U.S. do not belong to Native American communities but still carry bits of Native American DNA, inherited from European and African ancestors who had children with indigenous individuals during colonization and settlement. In a new study published 19th September in PLOS Genetics, Andrew Conley of the Georgia Institute of Technology and […]
  • IGF1 gene is essential to adult tendon growth, animal study shows September 19, 2019
    Tendon injuries are among the most common injuries seen in athletes at all levels, from weekend warriors to professional basketball players. For those who rupture their tendons, returning to the same level of physical activity they enjoyed before the injury is rare.
  • Researchers create new protocol to improve gene therapy tool production September 19, 2019
    A method to create a faster and lower cost alternative for a gene therapy tool has been developed by Boston University School of Medicine (BUSM) researchers.
  • Genetic variants with possible positive implications for lifestyle September 19, 2019
    A German and British research team lead by Technical University of Munich (TUM) has examined the interplay between genetics, cardiovascular disease and educational attainment in a major population study. Genetic variants which had been linked to educational attainment in other studies were observed in the subjects. The researchers found that these variants also had implications […]
  • Scientists develop new methodology to genetically modify lab mice and human cells September 19, 2019
    A team led by Cedars-Sinai has designed a rapid method to genetically alter laboratory mice and then used this method to produce personalized animal models of pediatric glioma, an aggressive type of malignant brain cancer in children.
Top